Trial reportBMJ open diabetes research & care2024
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes-Randomized Controlled Trial (PRISM-RCT) in Chinese patients with young-onset diabetes: design, methods and baseline characteristics.
Trial report in BMJ open diabetes research & care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04049149 (Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) in Chinese Patients With Young Onset Diabetes
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Precision nutrition-based interventions for the management of obesity in children and adolescents up to the age of 19 years.The Cochrane database of systematic reviews · 2025Pooled it
- Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes.Diabetes care · 2026Trial
- Multi-Dimensional Barriers for Work Productivity and Possible Solutions to Overcome Presenteeism in Young-Onset Diabetes: A Mixed-Methods Study.Diabetes, obesity & metabolism · 2026Article
- Young People With Type 2 Diabetes Are Under-Represented in Randomized Clinical Trials.Diabetes, obesity & metabolism · 2026Article
- Differential healthcare costs in individuals with type 2 diabetes and incident chronic kidney disease in Hong Kong: a latent class trajectory analysis.Diabetologia · 2026Article
- Phenotypic heterogeneity and polygenic risk scores in a family of maturity-onset diabetes of the young.JCEM case reports · 2026Article
- Redefining Diabetes and Creating Solutions-The Hong Kong Diabetes Register: Kelly West Award Lecture 2025.Diabetes care · 2026Article
- Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young-onset type-2 diabetes in Hong Kong.Diabetes, obesity & metabolism · 2026Article
- Integrated Management Strategies for Diabetes Mellitus and Hypertension: A Systematic Review.Cureus · 2026Review
- Recent Progress in Exploring Dietary Nutrition and Dietary Patterns in Periodontitis with a Focus on SCFAs.Nutrients · 2025Review
- Development of a Chinese-Specific Clinical Model to Predict Maturity-Onset Diabetes of the Young.Diabetes/metabolism research and reviews · 2025Article
- Young-onset type 2 diabetes-Epidemiology, pathophysiology, and management.Journal of diabetes investigation · 2025Review
- Cardiovascular abnormalities already occurred in newly-diagnosed patients with early-onset type 2 diabetes.Cardiovascular diabetology · 2025Article
- A 30-year case study of local implementation of global guidelines for data-driven diabetes management starting with the Hong Kong Diabetes Register.The Lancet regional health. Western Pacific · 2025Article
- From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.Biomedicines · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe designed and implemented a patient-centered, data-driven, holistic care model with evaluation of its impacts on clinical outcomes in patients with young-onset type 2 diabetes (T2D) for which there is a lack of evidence-based practice guidelines. RESEARCH DESIGN AND
methodsIn this 3-year Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes-Randomized Controlled Trial, we evaluate the effects of a multicomponent care model integrating use of information and communication technology (Joint Asia Diabetes Evaluation (JADE) platform), biogenetic markers and patient-reported outcome measures in patients with T2D diagnosed at ≤40 years of age and aged ≤50 years. The JADE-PRISM group received 1 year of specialist-led team-based management using treatment algorithms guided by biogenetic markers (genome-wide single-nucleotide polymorphism arrays, exome-sequencing of 34 monogenic diabetes genes, C-peptide, autoantibodies) to achieve multiple treatment goals (glycated hemoglobin (HbA1c) <6.2%, blood pressure <120/75 mm Hg, low-density lipoprotein-cholesterol <1.2 mmol/L, waist circumference <80 cm (women) or <85 cm (men)) in a diabetes center setting versus usual care (JADE-only). The primary outcome is incidence of all diabetes-related complications.
resultsIn 2020-2021, 884 patients (56.6% men, median (IQR) diabetes duration: 7 (3-12) years, current/ex-smokers: 32.5%, body mass index: 28.40±5.77 kg/m
conclusionsYoung-onset diabetes is characterized by complex etiologies with comorbidities including mental illness and lifecourse events. TRIAL REGISTRATION NUMBER: NCT04049149.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.